noscript

News and Announcements

Prescient Therapeutics Granted USPTO Allowances for Two PTX-200 Patents

  • Published August 08, 2016 10:40AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

4th August 2016, ASX Announcement

Clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) is pleased that the US Patent and Trademark Office (USPTO) has issued two notices of allowance under the PTX-200 patent families “Effective treatment of tumors and cancer with triciribine and related compounds” and “Compositions including triciribines and taxanes and methods of use thereof“.

The first allowance bears relevance to claims involving the intravenous dosing schedule of novel Akt inhibitor, PTX-200, including a method for identifying and treating patients with tumors in the pancreas, ovary or colon that have highly expressed Akt.

The second allowance has allowed claims bearing particular relevance to PTX’s ongoing breast cancer clinical trial, involving the use of PTX-200 with taxanes.

To view the full announcement, please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now